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Synopsis 
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and relates to high morbidity 
and mortality due to  thromboembolic events, especially ischemic stroke. During the last fifteen 
years, transcatheter ablation  has emerged as an effective therapeutic option to treat AF but carries a 
risk of possible complications. The occurrence of cerebrovascular accidents, both symptomatic and  
silent, is one of the most frequent and severe. Transcatheter AF ablation entails a relevant risk of 
silent cerebral ischemia (SCI) detected by means of Magnetic Resonance Imaging and many efforts 
have been directed to improve the safety of this procedure. 
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Introduction 
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias affecting 1-2% of the 
worldwide population and its burden is expected to rise in the next decades1,2. Prevalence of AF 
increases with age, from less than 0.4% at 40-50 years of age up to 15% over the age of 803,4. 
Independently from the presence of comorbidities, AF relates to enhanced mortality and 
thromboembolism5, particularly to the brain. 
The cerebral thromboembolic damage secondary to AF  may be clinically overt or appear as a silent 
phenomenon6. If symptomatic brain damage is easily diagnosed and has been thoroughly analyzed, 
the relationship between AF and silent cerebral ischemia (SCI) needs further evaluation.  
SCI have been proven not to be “really silent” from a clinical point of view and to deserve attention 
by the worldwide medical community, especially as possible complication of transcatheter 
ablation7. 
As a matter of fact, the presence of silent cerebral damage resulted in a higher incidence  of stroke, 
physical disability, death and with  cognitive function worsening8,9,10 In addition, a recent study11 
underlined that the greater SCI burden typical of patients with AF can negatively impact neuro-
psychological performance as compared with a control group.  
 
Cerebral ischemia and Atrial fibrillation ablation 
During the last fifteen years, transcatheter ablation of AF  has emerged as an effective therapeutic 
option to restore sinus rhythm (SR), relieve symptoms and prevent thromboembolic events in 
patients refractory or intolerant to antiarrhythmic medications12. 
As any invasive procedure AF ablation carries a risk of possible complications, whose the 
occurrence of cerebrovascular accidents is one of the most frequent and severe.  
If the incidence of clinically relevant brain alterations following AF ablation can reach  0.9% 13, the 
occurrence of SCI is much more common and  ranges from 7 to 50%.  This broad variation can be 
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attributed to the different patient characteristics,  anticoagulation protocol and type of energy used 
to perform the ablation among different studies14-17. 
Patients clinical characteristics such as age 18,19, previous episodes of AF20, presence of pre-ablation 
SCI 21, coronary artery disease,  left ventricular hypertrophy or dilatation14 as well as procedural 
aspects [i.e. intraprocedural cardioversion , activated clotting time (ACT) <250sec 7, complex 
fractionated atrial electrograms18] were associated with the occurrence of SCI  following 
transcatheter ablation.  
Being SCI related not only to AF itself but also to AF transcatheter ablation  performed indeed to 
cure this arrhythmia, our group, as other research teams, tested different interventional protocols, 
ablation tools and energy sources , in order to minimize the occurrence of such complication. 
The anatomical features and distribution of SCI occurring following transcatheter ablation represent 
a crucial and unresolved issue and need to be further investigated. In addition, if these lesions 
persist or disappear at follow-up 21,22 and their effective clinical impact remain still unclear and 
represent a matter of debate23.  Although computed tomography (CT) scans were previously 
performed to evaluate the possible occurrence of post AF ablation brain alterations 24-26 , more 
recently, magnetic resonance (MR) imaging has become the preferred technique used  to investigate 
this  problem because of its high sensitivity and accuracy. 
Accordingly, fruitful collaborations between cardiologists and neuro-radiologists have been started 
in many centers in order to  achieve thorough cerebral MR scans analyses of patients with AF. 
The aim of this  article is to discuss the current knowledge about post-AF ablation cerebral 
abnormalities with particular attention towards  their MR features.  
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Research Protocol on Cerebral ischemia following AF ablation 
In our experience we examined by means of cerebral MR imaging a large population of about 900 
AF patients undergoing AF transcatheter ablation, of which a group resulted that was affected by 
SCI following this intervention.   
In general, in all the studies focusing on cerebral ischemia following AF ablation performed by our 
group, all  patients included were evaluated by the protocol summarized below: 
• Medical history (specifically focused on AF subtype and duration, comorbidities and 
presence of underlying structural heart disease).  
• Thromboembolic risk assessment performed by means of systematic calculation of 
CHADS227and CHA2DS2VASc28 scores. 
• Pharmacological history (in particular focused on the anticoagulation regimen used). 
• Standardized neurological examination based on  the National Institute of Health Stroke 
Scale (NIHSS Scale) administered by certified neurologists (at the time of admission, after 
the neuroimaging investigation and during follow-up) in order to exclude clinical signs and 
symptoms suggestive of focal or global deficits. 
• Echocardiographic assessment (both transthoracic and transesophageal). 
• MR scans were performed one day before and the day following the ablation. All MRI scans 
were collected and assessed by two certified neuroradiologists blinded to clinical details. 
Eventually, a sub-group of patients underwent follow-up MR after 3 months. 
• Evaluation of cognitive function by means of Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS)29. 
• Different ablation technologies and protocols were evaluated.  
• Exclusion criteria have been described elsewhere7,11. 
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Cerebral MR imaging protocol and definition of cerebral ischemic lesions following AF 
transcatheter ablation 
The imaging protocol used in our center is summarized in Figure 1.   
Brain MRI examinations were obtained with a 8-channel head coil on Magnetom Avanto® 1,5 
Tesla (Siemens, Erlangen, Germany) following an imaging protocol including a sagittal T1- and 
Coronal T2-weighted spin echo sequence (repetition time/echo time 400/13 msec) and an axial T2-
Fluid Attenuated Inversion Recovery [FLAIR] (repetition time/echo time 8500/112 msec; TI, 2500 
msec) scan, with a 240 mm field of view, 5 mm section thickness and 154x256 matrix. A diffusion-
weighted (DW) and an ADC (apparent diffusion coefficient) mapping sequences with a single shot 
spin echo with echo-planar imaging technique (repetition time/echo time 3200/99 msec, field of 
view 230 mm, matrix 128x128, bandwidth 1502 Hz, gradient strength 22 mT, duration of diffusion 
gradient 31 msec, gradient separation 42 msec in 3 orthogonal directions, acquisition time 43 
seconds) was also used.  
 
Figure 1  Magnetic Resonance Imaging (MR) research protocol; DW: diffusion weighted; 
ADC: apparent diffusion coefficient. 
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A standardized definition of AF ablation-related Silent Cerebral Ischemia unfortunately is still 
lacking. In our studies an acute embolic lesion was defined as a focal hyperintense area on T2-
FLAIR sequences or isointense in T1-weighted images, not present at the pre-procedural scan, 
corresponding to a restricted diffusion signal in the DW sequence and confirmed by ADC mapping 
to rule out a shine-through artifact7. 
Peri-vascular spaces were differentiated from small (<3 mm) lacunar ischemic lesions on the basis 
of their location, form, surrounding gliosis and T2-FLAIR weighted sequences 30 (the former 
appearing as hypointense the latter as hyperintense). Leukoaraiosis was defined as bilateral and 
either patchy or diffuse areas of hyperintensity on T2- and hypointense on T1-weighted MRI 
sequences confined to the periventricular regions or extending into the centrum semiovale31. 
Size and localization of the focal lesions were recorded according the classification showed in Table 
1. 
 
Table 1.  Anatomical classification and brain distribution of silent cerebral ischemia. 
Dimensions 
• Small (<5 mm)  
• Medium (≥5 and < 10 mm) 
• Large (≥10 mm) 
Cerebral Hemisphere 
• Right hemisphere 
• Left hemisphere 
Brain Region 
• Frontal lobe 
• Parietal lobe 
• Temporal lobe 
• Occipital lobe 
• Cerebellum 
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• Basal ganglia  
• Nucleus caudatus 
• Internal capsula  
• Corpus callosum 
Brain tissue depth 
• Cortical region 
• Subcortical white matter 
• Deep white matter 
 
 
Main findings of the studies 
The prevalence of SCI reported in our studies ranges from 5 to 38.9%: more details on SCI 
incidence and different ablation protocols and techniques tested by our group are given in Table 2. 
SCI showed a cortical and bilateral distribution with a typical preferential localization within the 
context of the parietal and frontal lobes as well as in the cerebellum.  
 
 
 
 
 
 
 
9 
 
Table 2. Silent cerebral ischemia (SCI) incidence following atrial fibrillation trans-catheter ablation 
in our different studies. Pts: patients. ACT: activated clotting time; RF: radiofrequency; PVAC: 
pulmonary veins ablation catheter associated with duty-cycled radiofrequency generator. 
 
Pts (n) Anticoagulation 
protocol 
Source of energy 
used 
SCI incidence SCI predictors 
232 7 
Unfractioned 
Heparin,  
ACT > 250 sec 
Irrigated RF 14.0% 
Cardioversion  
ACT<250 sec 
95 32 
Unfractioned 
Heparin,  
ACT > 250 sec 
Irrigated RF 6.0% Cardioversion  
80 33 
Unfractioned 
Heparin,  
ACT > 300 sec 
Irrigated RF, 
Super irrigated RF 
7.5% 
5.0% 
ACT <320 sec 
108 15 
Unfractioned 
Heparin,  
ACT > 300 sec 
Irrigated RF 
Cryoballoon 
PVAC 
8.3% 
5.6% 
38.9% 
PVAC 
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Atlas of cerebral alterations following AF ablation 
The following MR images provide some examples of cerebral alterations occurring in patients with 
different clinical characteristics after AF thranscatether ablation performed with alternative ablation 
tools. 
 
Patient 1 
Cerebral MR imaging of a 64 years-old female patient with persistent AF who underwent irrigated 
RF ablation. (Figure 2). 
(A) Pre-procedural scan without brain lesions. 
(B) T2- FLAIR and DW images (DWI) post-procedural scans showing the appearance of a single 
bright cortical lesion in the right parietal lobe (max dimensions 6 x 4 mm) consistent with an acute 
embolic cerebral infarction (white arrows). 
(C) 3 months follow up T2- FLAIR scan demonstrates that the small lesion has disappeared. In 
order to better visualize the region of interest two adjacent images are provided. 
11 
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Patient 2 
Cerebral MR imaging of 67 years old female patient with paroxysmal AF (Figure 3). MR scans pre 
(row A) and post RF ablation with PVAC (row B): a new cortical-subcortical single ischemic lesion 
is present in left parietal lobe (max dimension 10 x 3 mm). 
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Patient 3 
Cerebral MR imaging of a 63 years old  male  with persistent AF.  This is an example of SCI 
occurring after irrigated RF ablation performed with a mean activated clotting time of 220 sec. 
Moreover an electrical cardioversion was administered at the end of this procedure (Figure 4). 
Post-procedural  cerebral MRI (row A) T2-FLAIR and DW image indicate a single new ischemic 
lesion in the left head of the caudate nucleus (white arrows) (max dimensions 4 x 4 mm). Three 
months follow up T2 FLAIR scans (row B) demonstrated the persistence of a lesion of reduced 
dimensions.  
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Patient 4 
Cerebral MRI of 71 years-old female, with CHA2DS2Vasc score 4, who underwent cryoablation for 
persistent AF (Figure 5).  
The T2 FLAIR scan (A) demonstrates multiple cortical-subcortical hyperintense cerebral lesions. 
However only one lesions in the superior frontal gyrus (white arrows ) is recent as demonstrated in 
the DW image (B).  The other lesions are attributable to older ischemic brain damage. 
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Patient 5 
Multiple new ischemic lesions following irrigated RF ablation are visible in the MR scans of a 54 
years old-female patient with paroxysmal AF (Figure 6).  
Pre-procedural (A), post-procedural (B) T2 FLAIR and post-procedural DW (C): the white arrows 
indicate new multiple lesions in the left cerebellum (max dimensions 8 x 6 mm). 
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Patient 6 
Cerebral MR imaging of a 59 years-old female with paroxysmal AF and hypertension (Figure 7).  
In Row A the basal  T2 Flair and DWI scans are showed. After irrigated RF ablation (row B) is 
visible in the right cerebellum  a new hyperintense lesion with reduced diffusion (white arrow).  
After three months of follow up a smaller lesion is still visible in T2-Flair image (row C). 
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Patient 7 
Cerebral scans of 64 years-old male with paroxysmal AF (Figure 8). This is another example of SCI 
detected after irrigated RF ablation followed by electrical cardioversion at the end of the procedure. 
The mean activated  clotting time was 250 sec. 
Post-procedural (row A) T2-FLAIR and DW image (row B) indicate two new bilateral lesions (max 
dimensions 20 x 10 mm), the first located in right occipital-parietal lobe and the second in the left 
parietal lobe.  
Three months follow up T2 FLAIR scans (row C) demonstrated  the disappearance of the first 
lesion and a reduction of the second one (white arrows). 
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Considerations regarding silent cerebral ischemia following atrial fibrillation transcatheter 
ablation. 
In our population experiencing silent cerebral ischemia, following AF transcatheter ablation  SCI 
prevalence ranges from 5 to 38,9%: this broad variation depends on the different ablation protocols 
and tools utilized (activating clotting time value, electrical cardioversion at the end of procedure, 
type of energy sources applied). Concerning the pathophysiology of silent embolic lesions, three 
main mechanisms are responsible for the occurrence of SCI during transcatheter ablation: clot 
formation, char formation and air/gas embolism. In particular, the following are potential causes of 
thromboembolism: endothelial disruption, electroporation injury, heating of circulating blood 
elements 34,35 and gaseous36 or solid embolism due to catheter movement within the left atria.  
SCI mostly showed a cortical and bilateral distribution with a typical preferential localization in the 
parietal and frontal lobes as well as in the cerebellum. These findings are in line with results 
previously reported by other groups although in smaller study populations. For instance, Schrickel 
et al14 outlined a similar distribution of periprocedural cerebral microemboli in the fronto-parietal 
regions and in the cerebellum in patients with persistent or paroxysmal atrial fibrillation undergoing 
transcatheter pulmonary vein isolation. The reasons for this preferential localization might be 
related to the high blood volume and to the vast distribution of the middle cerebral and vertebro-
basilar arteries, easily accessed by periprocedural microemboli.  
Despite the cortical localization of SCI, none of our patient with post-procedural cerebral alterations 
had neurological symptoms; this may sound surprising considering that most of the lesions were 
localized in the cortical region and in the parietal, frontal lobes and cerebellum. 
At present the neurocognitive implications of periprocedural SCI still result uncertain and many 
doubts concerning the persistence or the disappearing of these cerebral lesions at follow up need to 
be clarified  21,37,38. 
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In particular although a large study showed a lower incidence of cerebrovascular events and 
dementia among AF patients undergoing RF ablation compared with AF patients not treated with 
ablation 39, other experiences 22,40 highlighted the presence of some cognitive alterations after this 
type of  interventional procedure.  
Although we have some information about the neuropsychological significance of SCI due to AF 11  
further researches need to be performed  in order to fully understand the impact of new cerebral 
embolic lesions ablation related on cognitive function at long term follow up.  
 
Summary. 
Silent cerebral ischemia following transcatheter AF ablation are generally localized in the cortex of 
the frontal, parietal and cerebellar lobes with about half of the lesions persisting at mid-term follow-
up. 
It seems to be crucial to continue testing and optimizing AF ablation techniques and protocols  in 
order to reduce their possible embolic complications. In this regard,  cerebral MR scans of AF 
patients has emerged as fundamental evaluation tool.  
In addition, it is relevant to create a cardiological and radiological shared knowledge on cerebral 
damage secondary to AF, being the frequency of these problems already very high and expected to 
rise in the future decades. 
Eventually great attention should be paid to the long-term neurological impact of AF related silent 
cerebral damage. In the near future, more studies specifically investigating its influence on 
cognitive function are warranted . 
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